Endocrinology Research Analysis
June saw rapid advances in metabolic therapeutics and precision endocrinology. Multiple trials established the feasibility of oral small-molecule GLP-1 receptor agonists for weight loss and glycemic control, while mechanistic human-islet work clarified metabolic-state–dependent sites of GLP-1 action. Pharmacogenomic evidence showed melatonin acutely impairs β-cell function in MTNR1B risk carriers, highlighting immediate implications for personalized counseling. Translational liver RNA biology (g
Summary
June saw rapid advances in metabolic therapeutics and precision endocrinology. Multiple trials established the feasibility of oral small-molecule GLP-1 receptor agonists for weight loss and glycemic control, while mechanistic human-islet work clarified metabolic-state–dependent sites of GLP-1 action. Pharmacogenomic evidence showed melatonin acutely impairs β-cell function in MTNR1B risk carriers, highlighting immediate implications for personalized counseling. Translational liver RNA biology (glycoRNA) emerged as both a biomarker source and therapeutic lever in MASLD, underscoring inter-organ signaling as a targetable axis.
Selected Articles
1. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant.
A randomized, double-blind, placebo-controlled crossover trial (n=21) demonstrated that a single 5 mg dose of melatonin acutely worsened glucose tolerance and suppressed first-phase β-cell responsivity by about 40% in MTNR1B G-allele carriers but not in noncarriers; melatonin also altered insulin feedback and prevented insulin-induced hypoglycemia in carriers.
Impact: Delivers genotype-stratified, mechanistic RCT evidence that a widely used supplement can acutely impair β-cell function in genetic risk carriers, directly informing precision counseling and risk mitigation.
Clinical Implications: Clinicians should counsel at-risk patients—especially those with prediabetes or strong family history—about melatonin’s potential metabolic harm in MTNR1B carriers; where feasible, genotype-guided recommendations on sleep aids and dosing/timing may be considered pending chronic-use data.
Key Findings
- Melatonin worsened glucose tolerance in MTNR1B G-allele carriers but not in noncarriers.
- First-phase β-cell responsiveness to glucose was reduced by ~40% in carriers under melatonin.
- Melatonin disrupted insulin feedback and prevented insulin-induced hypoglycemia in carriers.
2. HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
A multicenter phase 2 randomized, double-blind trial (n=235) showed once-daily oral HRS-7535 achieved dose-dependent weight loss at 26 weeks (up to −9.36%; placebo-adjusted up to −6.87% at 180 mg) with mostly mild-to-moderate gastrointestinal adverse events, supporting feasibility of an oral GLP-1 therapeutic class.
Impact: Provides early randomized evidence that an oral small-molecule GLP-1RA can deliver clinically meaningful weight loss, potentially transforming access and adherence beyond injectables.
Clinical Implications: If replicated in larger, longer, and more diverse studies with active comparators, oral GLP-1RAs may become alternatives to injectables for obesity care, broadening patient choice and potentially improving adherence.
Key Findings
- Dose-dependent weight loss to −9.36% at 180 mg (placebo-adjusted up to −6.87%).
- Statistically significant placebo-adjusted differences from 60 mg and above.
- GI events were most common and mostly mild-to-moderate, especially during dose escalation.
3. Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.
A translational mechanistic study using human donor islets across metabolic states showed liraglutide enhances glucose-stimulated insulin secretion in islets from glucose-intolerant donors but not from normoglycemic donors; GLP-1R expression declined with rising HbA1c, and complementary brain (tanycyte-mediated) vs islet mechanisms were delineated by metabolic state.
Impact: Provides human-tissue evidence for metabolic-state–dependent efficacy and site of GLP-1 action, informing biomarker development and precision patient selection for incretin therapy.
Clinical Implications: Supports stratifying GLP-1RA candidates by metabolic phenotype: greater islet-secretory benefits in glucose intolerance, with brain-mediated effects predominating in earlier/healthier states; motivates development of response biomarkers.
Key Findings
- Liraglutide enhanced GSIS in islets from glucose-intolerant donors but not from normoglycemic donors.
- GLP-1R mRNA in T2D donor islets declined with rising HbA1c.
- Framework: brain tanycyte-mediated actions in health vs direct islet effects in glucose intolerance.
4. Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.
This translational study shows glycosylated small RNAs (glycoRNAs) are produced in human liver and reduced in MASLD due to downregulation of SIDT1 and DTWD2; AAV-mediated restoration of these mediators attenuated MASH in mice. The work positions glycoRNA biogenesis as both a biomarker source and a therapeutic lever.
Impact: First demonstration linking impaired glycoRNA biogenesis to MASLD with in vivo rescue, opening an RNA-based diagnostic and therapeutic axis for metabolic liver disease.
Clinical Implications: GlycoRNA species and their biosynthetic mediators may become minimally invasive biomarkers for MASLD severity and potential targets for disease modification; early-phase AAV-based approaches merit translational evaluation.
Key Findings
- GlycoRNAs are synthesized in human liver and decreased in MASLD.
- Downregulation of SIDT1/DTWD2 drives glycoRNA loss and worsens lipid/inflammatory signaling.
- AAV restoration of SIDT1/DTWD2 attenuates MASH in mouse models.
5. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
The SOLSTICE multicenter phase 2b RCT (n=404 treated) showed once-daily oral elecoglipron produced clinically meaningful glycemic reductions with safety and tolerability consistent with the GLP-1RA class, supporting advancement to phase 3.
Impact: Demonstrates efficacy of an oral small-molecule GLP-1RA, with potential to transform clinical access, adherence, and delivery versus injectables.
Clinical Implications: If phase 3 confirms efficacy and safety, elecoglipron could extend GLP-1RA use to patients unwilling or unable to use injectables and may alter T2D treatment algorithms.
Key Findings
- Randomized, double-blind, placebo-controlled phase 2b trial across nine countries (n=404 treated).
- Once-daily oral elecoglipron achieved clinically meaningful glycemic reductions versus placebo.
- Safety and tolerability were consistent with GLP-1RA class profiles.